Organophosphate ingestion: checking a junior's atropine order
A 35-year-old male farm worker is brought to the ESIC emergency department 40 minutes after swallowing 'about two mouthfuls' of an organophosphate insecticide from an unlabelled bottle, while intoxicated. He is drowsy but rousable. Pulse 46/min, BP 88/56 mmHg, respiratory rate 8/min and shallow, SpO2 84% on room air, copious oral and tracheal secretions, pinpoint pupils, generalised muscle fasciculations, and a strong solvent odour on the breath. Capillary glucose is 96 mg/dL. The department has atropine 0.6 mg/mL ampoules (30 in stock), pralidoxime 500 mg vials (6 in stock), one functioning suction apparatus and a bag-valve mask. The junior resident has written 'Atropine 0.6 mg IV stat, repeat if needed' and asks the ward pharmacist to check the order and prepare the drugs while the anaesthetist is being called.
1. Is the resident's atropine order adequate? State the initial dose, the escalation rule and the clinical endpoints you would use to judge that atropinisation is adequate.
Read the worked answer
The order is not adequate. 0.6 mg is a diagnostic dose left over from older practice and is far too small; under-dosing atropine is the commonest avoidable cause of death in organophosphate poisoning. Also, 'repeat if needed' gives no escalation rule and no endpoint, so the nursing staff will under-treat.
Recommended approach.
- Airway and oxygenation first: suction, bag-valve-mask ventilation, oxygen. Hypoxia drives the bradycardia and must be corrected alongside atropine; atropine will not work well in a hypoxic patient.
- Initial atropine 1–2 mg IV bolus (weight-based alternatives of about 0.02–0.05 mg/kg are also used), then double the dose every 3–5 minutes - 2, 4, 8, 16, 32 mg - until the endpoints are met. There is no fixed maximum dose; large cumulative amounts (hundreds of milligrams) are sometimes needed, so stock must be checked early.
Endpoints of adequate atropinisation:
- Secretions in the chest and mouth have dried (the single most important endpoint).
- Heart rate above about 80/min.
- Systolic BP above about 80–90 mmHg.
- Warm, dry skin and resolved bronchospasm.
Pupil size and heart rate alone are unreliable. Tachycardia from hypoxia or from the patient's distress is not a reason to withhold atropine. Remember that atropine reverses only the muscarinic effects - fasciculations and muscle weakness are nicotinic and need pralidoxime and ventilation.
2. Explain the role and timing of pralidoxime in this patient. Name two drugs or interventions that must be avoided and give the pharmacological reason for each.
Read the worked answer
Pralidoxime. It is an oxime that reactivates phosphorylated acetylcholinesterase by displacing the phosphate group, but only while the enzyme–inhibitor complex is still capable of being reactivated - that is, before 'ageing' of the complex. Ageing is fastest with dimethyl phosphates and slower with diethyl compounds, so the exact window cannot be assumed; the practical rule is to give the oxime as early as possible, ideally within the first hours, and it is of most value within 24–48 hours. A typical adult regimen is 1–2 g (about 30 mg/kg) intravenously over 15–30 minutes, followed by an infusion of about 8 mg/kg/hour, continued for at least 24–48 hours depending on the clinical course. It is given alongside atropine, not instead of it, and it is the antidote for the nicotinic (fasciculation and weakness) component.
Must be avoided:
- Succinylcholine for intubation - plasma cholinesterase is also inhibited by the organophosphate, so the neuromuscular block is unpredictable and dangerously prolonged; use a non-depolarising agent with reduced dose and monitoring instead.
- Morphine and other respiratory depressants - the patient already has a depressed respiratory drive and central depression; opioids worsen hypoventilation and obscure the neurological picture.
Also avoid gastric lavage without a protected airway (risk of aspiration of solvent and gastric contents), and avoid mouth-to-mouth ventilation - rescuer exposure is a real hazard; use a bag-valve mask. Staff must wear gloves and gowns and the patient's clothing should be removed and bagged, since dermal contamination continues to poison both patient and carers.
3. On day 3 the patient is fully conscious, secretions have dried and pupils are normal, but he now has neck flexor weakness, difficulty lifting his arms and respiratory distress with a falling oxygen saturation. What is happening and how should it be managed?
Read the worked answer
This is the intermediate syndrome of organophosphate poisoning - a delayed neuromuscular junction failure that appears typically 24–96 hours after exposure, after the acute cholinergic crisis has resolved and before delayed polyneuropathy would occur. The pupils are normal and secretions are dry, which is exactly why it is missed: the classic mistake is to treat this as recurrent cholinergic crisis and give more atropine, which does nothing and delays the correct action.
Pathophysiology. Prolonged inhibition and possibly down-regulation of post-synaptic nicotinic receptors at the motor end plate produces proximal muscle weakness - neck flexors, shoulder girdle, respiratory muscles and cranial nerves. It is a nicotinic problem, so atropine is irrelevant.
Management.
- Airway and ventilation are the treatment. Move to a high-dependency or ICU setting, monitor oxygen saturation and, if vital capacity is falling (a practical trigger is below about 15–20 mL/kg, or inability to lift the head), intubate and ventilate electively rather than waiting for a crisis.
- Watch for aspiration and bulbar palsy; keep nil by mouth until swallowing is safe.
- Maintain electrolytes and nutrition; treat superadded infection.
- Do not give further atropine; there is no proven antidote once the syndrome is established. Recovery is usually over 1–2 weeks but can take longer.
Convey clearly to the team that this is not recurrence of cholinergic crisis, because the wrong reflex response here is a large atropine bolus.